{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124581","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.592308+00:00","generated_at":"2026-05-30T02:05:19.858613+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026","bullets":["Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.","Net loss of $21.2M ($0.35/share) vs $23.0M ($0.56/share) in Q3 2023.","R&D expenses rose to $17.7M from $14.7M due to increased clinical trial costs for PYX-201 and PYX-106.","Preliminary Phase 1 data for lead ADC PYX-201 to be presented at investor event on Nov 20, 2024; 80 patients dosed.","Phase 1 data for PYX-106 (Siglec-15 antibody) expected by year-end 2024; 45 patients dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124581","json":"https://secwatch.observer/filing/0000950170-24-124581.json","markdown":"https://secwatch.observer/filing/0000950170-24-124581.md","text":"https://secwatch.observer/filing/0000950170-24-124581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/0000950170-24-124581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/pyxs-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:05:19.858613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}